FBLG trades 20620.6% below Wall Street's consensus target of $180.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FBLG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, FibroBiologics, Inc. Common Stock (FBLG) has a Wall Street consensus price target of $180.00, based on estimates from 3 covering analysts. With the stock currently trading at $0.87, this represents a potential upside of +20620.6%. The company has a market capitalization of $2M.
Analyst price targets range from a low of $180.00 to a high of $180.00, representing a 0% spread in expectations. The median target of $180.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FBLG trades at a trailing P/E of -0.1x. Analysts expect EPS to grow +49.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
MESOMesoblast Limited | $1.8B | $14.33 | $11.50 | -19.7% | Buy | — | 11 |
NKTRNektar Therapeutics | $1.4B | $73.15 | $149.60 | +104.5% | Buy | — | 33 |
MDXGMiMedx Group, Inc. | $605M | $4.07 | $10.00 | +145.7% | Buy | — | 15 |
RGENRepligen Corporation | $8.0B | $141.46 | $158.67 | +12.2% | Buy | 70.6x | 24 |
FATEFate Therapeutics, Inc. | $349M | $2.99 | $5.50 | +83.9% | Buy | — | 31 |
CELCCelcuity Inc. | $5.3B | $108.58 | $153.22 | +41.1% | Buy | — | 12 |
VCELVericel Corporation | $2.4B | $46.56 | $52.67 | +13.1% | Buy | 98.6x | 14 |
RCUSArcus Biosciences, Inc. | $3.0B | $29.98 | $31.00 | +3.4% | Buy | — | 18 |
ILMNIllumina, Inc. | $29.5B | $194.33 | $156.27 | -19.6% | Buy | 37.1x | 50 |
TMOThermo Fisher Scientific Inc. | $192.4B | $517.60 | $592.45 | +14.5% | Buy | 20.8x | 42 |
Quick answers to the most common questions about buying FBLG stock.
The consensus Wall Street price target for FBLG is $180, representing 20620.6% upside from the current price of $0.8687. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
FBLG has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $180 implies 20620.6% upside from current levels.
FBLG's current price is $0.8687 with a consensus target of $180 (20620.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $180 for FBLG, while the most conservative target is $180. The consensus of $180 represents the median expectation. These targets typically reflect 12-month expectations.
FBLG is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FBLG stock forecast based on 3 Wall Street analysts shows a consensus price target of $180, with estimates ranging from $180 (bear case) to $180 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on FBLG, with a "Buy" consensus rating and $180 price target (20620.6% upside). 2 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FBLG analyst price targets range from $180 to $180, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $180 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.